Yang Q, Xu J, Gu J, Shi H, Zhang J, Zhang J, et al. Extracellular vesicles in Cancer Drug Resistance: roles, mechanisms, and implications. Adv Sci (Weinh). 2022;9:e2201609. https://doi.org/10.1002/advs.202201609.

Article  CAS  PubMed  Google Scholar 

De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95:2279–97. https://doi.org/10.1007/s00204-021-03063-7.

Article  CAS  PubMed Central  Google Scholar 

Ward RA, Fawell S, Floc’h N, Flemington V, McKerrecher D, Smith PD. Challenges and opportunities in Cancer Drug Resistance. Chem Rev. 2021;121:3297–351. https://doi.org/10.1021/acs.chemrev.0c00383.

Article  CAS  PubMed  Google Scholar 

Song H, Liu D, Dong S, Zeng L, Wu Z, Zhao P, et al. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther. 2020;5:193. https://doi.org/10.1038/s41392-020-00300-w.

Article  PubMed  PubMed Central  Google Scholar 

Di Donato M, Medici N, Migliaccio A, Castoria G, Giovannelli P. Exosomes: emerging modulators of pancreatic Cancer Drug Resistance. Cancers (Basel). 2023;15. https://doi.org/10.3390/cancers15194714.

Gonzalez-Fierro A, Dueñas-González A. Drug repurposing for cancer therapy, easier said than done. Semin Cancer Biol. 2021;68:123–31. https://doi.org/10.1016/j.semcancer.2019.12.012.

Article  PubMed  Google Scholar 

Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8:204. https://doi.org/10.1038/s41392-023-01468-7.

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Zhao Y, Liu S, Zhang J, Assaraf YG, Cui W, et al. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance. Drug Resist Updat. 2022;61:100821. https://doi.org/10.1016/j.drup.2022.100821.

Article  CAS  PubMed  Google Scholar 

Jo H, Shim K, Jeoung D. Targeting HDAC6 to Overcome Autophagy-promoted Anti-cancer Drug Resistance. Int J Mol Sci. 2022;23. https://doi.org/10.3390/ijms23179592.

Chan YT, Lu Y, Wu J, Zhang C, Tan HY, Bian ZX, et al. CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives. Theranostics. 2022;12:3329–44. https://doi.org/10.7150/thno.71144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021;57:100770. https://doi.org/10.1016/j.drup.2021.100770.

Article  CAS  PubMed  Google Scholar 

Namee NM, O’Driscoll L. Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer. 2018;1870:123–36. https://doi.org/10.1016/j.bbcan.2018.07.003.

Article  CAS  PubMed  Google Scholar 

Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on Cancer Drug Resistance. Cancers (Basel). 2022;15. https://doi.org/10.3390/cancers15010062.

Qin Y, Ashrafizadeh M, Mongiardini V, Grimaldi B, Crea F, Rietdorf K, et al. Autophagy and cancer drug resistance in dialogue: pre-clinical and clinical evidence. Cancer Lett. 2023;570:216307. https://doi.org/10.1016/j.canlet.2023.216307.

Article  CAS  PubMed  Google Scholar 

Pi M, Kuang H, Yue C, Yang Q, Wu A, Li Y, et al. Targeting metabolism to overcome cancer drug resistance: a promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resist Updat. 2022;61:100822. https://doi.org/10.1016/j.drup.2022.100822.

Article  CAS  PubMed  Google Scholar 

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34. https://doi.org/10.1038/nrd1984.

Article  CAS  PubMed  Google Scholar 

Gonçalves AC, Richiardone E, Jorge J, Polónia B, Xavier CPR, Salaroglio IC, et al. Impact of cancer metabolism on therapy resistance - clinical implications. Drug Resist Updat. 2021;59:100797. https://doi.org/10.1016/j.drup.2021.100797.

Article  CAS  PubMed  Google Scholar 

Wang J, Tian T, Li X, Zhang Y. Noncoding RNAs emerging as drugs or drug targets: their Chemical Modification, Bio-conjugation and Intracellular Regulation. Molecules. 2022;27. https://doi.org/10.3390/molecules27196717.

Zahedipour F, Jamialahmadi K, Karimi G. The role of noncoding RNAs and sirtuins in cancer drug resistance. Eur J Pharmacol. 2020;877:173094. https://doi.org/10.1016/j.ejphar.2020.173094.

Article  CAS  PubMed  Google Scholar 

Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 2018;41:1–25. https://doi.org/10.1016/j.drup.2018.11.001.

Article  PubMed  Google Scholar 

Kong M, Yu X, Guo W, Guo R. The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors. Int J Biol Sci. 2023;19:4834–48. https://doi.org/10.7150/ijbs.87028.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang Z, Zhang C, Luo Y, Zhang G, Wu P, Sun N, et al. RNA N(6) -methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: current landscape and therapeutic potential. Clin Transl Med. 2021;11:e525. https://doi.org/10.1002/ctm2.525.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piperi C, Markouli M, Gargalionis AN, Papavassiliou KA, Papavassiliou AG. Deciphering glioma epitranscriptome: focus on RNA modifications. Oncogene. 2023;42:2197–206. https://doi.org/10.1038/s41388-023-02746-y.

Article  CAS  PubMed  Google Scholar 

Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1–11. https://doi.org/10.1016/j.drup.2018.03.001.

Article  PubMed  Google Scholar 

Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023;8:69. https://doi.org/10.1038/s41392-023-01341-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li B, Jiang J, Assaraf YG, Xiao H, Chen ZS, Huang C. Surmounting cancer drug resistance: new insights from the perspective of N(6)-methyladenosine RNA modification. Drug Resist Updat. 2020;53:100720. https://doi.org/10.1016/j.drup.2020.100720.

Article  PubMed  Google Scholar 

Liu Z, Zou H, Dang Q, Xu H, Liu L, Zhang Y, et al. Biological and pharmacological roles of m(6)a modifications in cancer drug resistance. Mol Cancer. 2022;21:220. https://doi.org/10.1186/s12943-022-01680-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68:100938. https://doi.org/10.1016/j.drup.2023.100938.

Article  CAS  PubMed  Google Scholar 

Du B, Shim JS. Targeting epithelial-mesenchymal transition (EMT) to Overcome Drug Resistance in Cancer. Molecules. 2016;21. https://doi.org/10.3390/molecules21070965.

Xie W, Sun H, Li X, Lin F, Wang Z, Wang X. Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell Int. 2021;21:434. https://doi.org/10.1186/s12935-021-02136-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022;13:877–919. https://doi.org/10.1007/s13238-021-00846-7.

Article  CAS